BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

10034	Companies
204206	Keywords
134570	Articles
108324	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 11/04/2025 at 09:10, 4 months 11 days ago

BioNxt Receives European Patent Notification for Cladribine Thin-Film

Multiple Sclerosis Oral Therapies Cladribine European Patent BioNxt
PRESS RELEASE

published on 11/04/2025 at 09:05, 4 months 11 days ago

BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
BioNxt Solutions Inc. receives 'Intention to Grant' notification from European Patent Office for sublingual cladribine thin-film formulation for MS treatment, securing extensive IP protection across Europe and Eurasia

BioNxt Solutions Inc. European Patent Office MS Treatment Sublingual Thin-Film Global Patent Coverage
BRIEF

published on 10/30/2025 at 08:10, 4 months 17 days ago

BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

Multiple Sclerosis Drug Delivery BioNxt Solutions Eurasian Patent Patent Strategy
PRESS RELEASE

published on 10/30/2025 at 08:05, 4 months 17 days ago

BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
BioNxt Solutions Inc. receives "Readiness to Grant" notification from EAPO for comprehensive patent application on sublingual delivery of anticancer drugs for autoimmune neurodegenerative diseases, including lead product BNT23001 for MS treatment. Patent protection strengthens commercialization strategy

BioNxt Solutions Inc. Patent Application Sublingual Drug Delivery Anticancer Drugs EAPO
BRIEF

published on 10/21/2025 at 09:10, 4 months 25 days ago

BioNxt Initiates Sublingual Cladribine Study for MS Treatment Optimization

Multiple Sclerosis Bioavailability Drug Delivery Bioequivalence Study Sublingual Cladribine
PRESS RELEASE

published on 10/21/2025 at 09:05, 4 months 25 days ago

BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
BioNxt Solutions Inc. announces a large-mass animal bioequivalence study for sublingual Cladribine formulation, targeting multiple sclerosis treatment, to optimize dosage parameters for upcoming human study

BioNxt Solutions Inc. Multiple Sclerosis Treatment Bioequivalence Study Drug Delivery Technologies Sublingual Cladribine Formulation
BRIEF

published on 10/10/2025 at 01:55, 5 months 6 days ago

BioNxt Solutions Addresses AGM Voting Amid Postal Strike

AGM Voting Marketing Campaign Canada Post Strike Proxy Submission
PRESS RELEASE

published on 10/10/2025 at 01:50, 5 months 6 days ago

BioNxt Solutions Provides Update To Annual General Meeting Matters Due To Canadian Postal Strike And IR Activities
BioNxt Solutions Inc. provides alternative voting options for shareholders due to Canada Post mail strike. Annual general meeting details and proxy voting instructions shared

Annual General Meeting Shareholders BioNxt Solutions Inc. Proxy Voting Voting Options
BRIEF

published on 10/09/2025 at 09:10, 5 months 6 days ago

BioNxt Completes Fast-Track Patent Filing for MS Treatment

Multiple Sclerosis Cladribine Patent Filing BioNxt Solutions Sublingual Delivery
PRESS RELEASE

published on 10/09/2025 at 09:05, 5 months 6 days ago

BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
BioNxt Solutions Inc. completes Track One priority patent filing with USPTO for sublingual thin-film cladribine formulation (BNT23001) targeting MS & other autoimmune diseases. Strategic move to strengthen IP position & advance regulatory approvals

BioNxt Solutions Inc. Multiple Sclerosis Patent Filing Sublingual Thin-Film Cladribine Formulation

Accesswire

Published on 03/15/2026 at 23:25, 9 hours 35 minutes ago

Tunkillia 'Phase 2' Resource Upgrade Drilling Begins
Published on 03/15/2026 at 18:00, 15 hours ago

SEG Announced 2025 Annual Results Initiating First Special Dividend Distribution Payout Ratio Reached 88% Newly Signed Orders Exceeded RMB100-Billion Mark for the Second Consecutive Year
Published on 03/13/2026 at 23:00, 2 days 10 hours ago

CORRECTION FROM SOURCE: EV Nickel Announces Maiden Mineral Resource Estimate for Gemini North Nickel Zone
Published on 03/13/2026 at 23:00, 2 days 10 hours ago

Redwood AI Announces Platform Name Change and Appointment of Dr. Mark Dybul as Public Safety & Defense Advisor
Published on 03/13/2026 at 21:30, 2 days 11 hours ago

Alset AI Announces Closing of Shares for Debt Transaction

View all ACCESSWIRE

EQS Group

Published on 03/16/2026 at 08:05, 54 minutes ago

Triton Partners successfully closes Fund 6 at €5.5 billion target
Published on 03/16/2026 at 08:05, 54 minutes ago

NX Europe to Participate in "LogiPharma 2026" in Vienna, Austria
Published on 03/16/2026 at 08:05, 54 minutes ago

JAR Capital Group Appoints Francois R. Farjallah as Vice Chairman
Published on 03/16/2026 at 08:00, 59 minutes ago

Coinsilium Group Limited: Coinsilium Makes Strategic Venture-Building Investment in the Prediction Markets Sector
Published on 03/16/2026 at 08:00, 59 minutes ago

Transaction in Own Shares

Les Echos

Published on 03/16/2026 at 08:30, 30 minutes ago

CDA - Update on CDA' parks solarization program
Published on 03/13/2026 at 19:50, 2 days 13 hours ago

Availability of ENGIE’S 2025 Universal Registration Document
Published on 03/13/2026 at 18:05, 2 days 14 hours ago

Availability of the 2025 Universal Registration Document of OPmobility SE
Published on 03/13/2026 at 07:30, 3 days 1 hour ago

BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE
Published on 03/12/2026 at 18:00, 3 days 15 hours ago

NEW OR RENEWED AGREEMENTS BETWEEN EURAZEO AND CERTAIN FAMILY SHAREHOLDERS

View all LES ECHOS COMFI WIRE